- In addition, the Company expects to be in a position to report data from the APOLLO trial in 2017 and, assuming positive data, to submit a New Drug Application (NDA) and Marketing Authorisation Application (MAA) for patisiran in late 2017.
Catalyst
Slingshot members are tracking this event:
Phase 3 data due of Patisiran APOLLO trial for Familial Amyloidotic Polyneuropathy in Patients with ATTR due in Mid-2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALNY |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 20, 2017
Occurred Source:
http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1041081
Related Projects
Related Keywords
Phase 3 Data, Patisiran, Apollo Trial, Familial Amyloidotic Polyneuropathy, Attr, Nda, Bpc
